Suppression of Lewis lung tumor development in alpha 1,3 galactosyltransferase knock-out mice.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Anticancer Research

• Publication date

  2004-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 15161001
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New Perspectives in Dendritic Cell-Based Cancer Immunotherapy

  2012cited by this paper
• The In Vitro and In Vivo Effects of Anti-Galactose Antibodies on Endothelial Cell Activation and Xenograft Rejection 1

  2003cited by this paper
• Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.

  2003cited by this paper
• Cancer vaccines, a critical review--Part II.

  2002cited by this paper
• Rituximab: Mechanism of action and resistance.

  2002cited by this paper
• Direct killing of xenograft cells by CD8+ T cells of discordant xenograft recipients1

  2002cited by this paper
• The Role of T Cell Help in the Production of Antibodies Specific for Galα1–3Gal1

  2002cited by this paper
• Immunologic mechanisms of antitumor activity.

  2002cited by this paper
• Induction of Cytolytic Anti-Gal Antibodies in α-1,3-Galactosyltransferase Gene Knockout Mice by Oral Inoculation with Escherichia coli O86:B7 Bacteria

  2002cited by this paper
• The role of T cell help in the production of antibodies specific for Gal alpha 1-3Gal.

  2002cited by this paper
• Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer?

  2001cited by this paper
• Human monocytes bind to ligands on porcine endothelium containing the Gal α (1,3)-Gal antigen

  2000cited by this paper
• Therapeutic vaccination for cancer.

  2000cited by this paper
• Differential immune responses to alpha-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation.

  2000cited by this paper
• Human monocytes bind to ligands on porcine endothelium containing the gal alpha (1,3)-Gal antigen.

  2000cited by this paper
• T cells interacting with the alpha-Gal epitope: studies in alpha1, 3Galactosyltransferase knock-out mice.

  2000cited by this paper
• Induction of complement attack on human cells by Gal(alpha1,3)Gal xenoantigen expression as a gene therapy approach to cancer

  1999cited by this paper
• How tumors escape immune destruction and what we can do about it

  1999cited by this paper
• IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients.

  1999cited by this paper
• Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.

  1999cited by this paper
• Eliciting hyperacute xenograft response to treat human cancer: alpha(1,3) galactosyltransferase gene therapy.

  1998cited by this paper
• Evaluation of the Galα1-3Gal Epitope as a Host Modification Factor Eliciting Natural Humoral Immunity to Enveloped Viruses

  1998cited by this paper
• A murine model of antibody-mediated hyperacute rejection by galactose-alpha(1,3)galactose antibodies in Gal o/o mice.

  1998cited by this paper
• Ratio of IgG: IgM antibodies to sialyl LewisX and GM3 correlates with tumor growth after immunization with melanoma‐cell vaccine with different adjuvants in mice

  1998cited by this paper
• GM‐CSF and B7‐1 (CD80) co‐stimulatory signals co‐operate in the induction of effective anti‐tumor immunity in syngeneic mice

  1997cited by this paper
• Heterogeneity of human anti-pig natural antibodies cross-reactive with the Gal(alpha1,3)Galactose epitope.

  1997cited by this paper
• Human natural killer lymphocytes directly recognize evolutionarily conserved oligosaccharide ligands expressed by xenogeneic tissues.

  1997cited by this paper
• alpha 1,3-Galactosyltransferase-deficient mice produce naturally occurring cytotoxic anti-Gal antibodies.

  1996cited by this paper
• Carbohydrate antigens as targets for active specific immunotherapy

  1996cited by this paper
• alpha 1,3-Galactosyltransferase-deficient mice produce naturally occurring cytotoxic anti-Gal antibodies.

  1996cited by this paper
• Suppression of α-galactosyl epitopes synthesis and production of the natural anti-Gal antibody: a major evolutionary event in ancestral Old World primates

  1995cited by this paper
• Gal alpha(1,3)Gal is the major xenoepitope expressed on pig endothelial cells recognized by naturally occurring cytotoxic human antibodies.

  1994cited by this paper
• Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal:beta-D-Gal(1,4)-D-GlcNAc alpha(1,3)-galactosyltransferase cDNA.

  1990cited by this paper
• Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora

  1988cited by this paper
• Loss of expression of transplantation antigens encoded by the H-2K locus on Lewis lung carcinoma cells and its relevance to the tumor's metastatic properties.

  1983cited by this paper

• Genomic Analysis of Glycosyltransferases Responsible for Galactose-α-1,3-Galactose Epitopes in Streptococcus pneumoniae: Implications for Broadly Protective Vaccination Strategy

  2025cites this paper
• Combination immunotherapy for high-risk resected and metastatic melanoma patients.

  2014cites this paper
• Cellular Immunotherapy Study of Prostate Cancer Patients and Resulting IgG Responses to Peptide Epitopes Predicted From Prostate Tumor-associated Autoantigens

  2013cites this paper
• Chapter 29 – HyperAcute Vaccines: A Novel Cancer Immunotherapy

  2013cites this paper
• A novel method to display [gal alpha1, 3 gal] antigens on human leukemic cells for preparation of anti-leukemia vaccines.

  2009cites this paper
• Real-time PCR to determine transgene copy number and to quantitate the biolocalization of adoptively transferred cells from EGFP-transgenic mice.

  2008cites this paper
• Anti-&agr;Gal-dependent complement-mediated cytotoxicity in metastatic melanoma

  2006cites this paper
• Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing α(1,3)galactosyl epitopes

  2005cites this paper
• Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes.

  2005cites this paper